[go: up one dir, main page]

AR132710A1 - ANTI-MET ANTIBODIES, ADCs, THEIR COMPOSITIONS AND USES - Google Patents

ANTI-MET ANTIBODIES, ADCs, THEIR COMPOSITIONS AND USES

Info

Publication number
AR132710A1
AR132710A1 ARP240101252A ARP240101252A AR132710A1 AR 132710 A1 AR132710 A1 AR 132710A1 AR P240101252 A ARP240101252 A AR P240101252A AR P240101252 A ARP240101252 A AR P240101252A AR 132710 A1 AR132710 A1 AR 132710A1
Authority
AR
Argentina
Prior art keywords
antibody
antigen
binding portion
seq
amino acid
Prior art date
Application number
ARP240101252A
Other languages
Spanish (es)
Inventor
Ana Leticia Maragno
Vesela Kostova
Sabine Plantier
Sandra Haumont
Toumelin-Braizat Gatane Le
Laura Bresson
Michael Monrad Grandal
Original Assignee
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Servier Lab filed Critical Servier Lab
Publication of AR132710A1 publication Critical patent/AR132710A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente invención se refiere a un nuevo anticuerpo recombinante o porción de unión a antígeno del mismo dirigido a MET, así como a ADC que comprenden este anticuerpo o porción de unión a antígeno del mismo, composiciones que comprenden este anticuerpo o porción de unión a antígeno del mismo, composiciones que comprende ADC que comprenden dicho anticuerpo anti-MET o porción de unión a antígeno del mismo, al uso de dicho anticuerpo o porción de unión a antígeno del mismo o de dichos ADC o de dichas composiciones que comprenden anticuerpo anti-MET o ADC anti-MET. Reivindicación 1: Un anticuerpo anti-MET o una porción de unión a antígeno del mismo, en donde dicho anticuerpo se selecciona del grupo que consiste en: a. un anticuerpo cuyas H-CDR1, H-CDR2, H-CDR3 comprenden las secuencias de aminoácidos de las SEQ ID Nº 1, 2, y 3, respectivamente; b. un anticuerpo cuyas L-CDR1, L-CDR2, L-CDR3 comprenden las secuencias de aminoácidos de las SEQ ID Nº 4, 5, y 6, respectivamente; c. un anticuerpo cuyo VH es al menos un 90% idéntico en secuencia a la secuencia de aminoácidos de la SEQ ID Nº 7; d. un anticuerpo cuyo VL es al menos un 90% idéntico en secuencia a la secuencia de aminoácidos de la SEQ ID Nº 8; e. un anticuerpo cuyo VH comprende la secuencia de aminoácidos de la SEQ ID Nº 7; f. un anticuerpo cuyo VL comprende la secuencia de aminoácidos de la SEQ ID Nº 8; g. un anticuerpo cuya HC es al menos un 90% idéntica en secuencia a la secuencia de aminoácidos de la SEQ ID Nº 11 o 13; h. un anticuerpo cuya LC es al menos un 90% idéntica en secuencia a la secuencia de aminoácidos de la SEQ ID Nº 12 o 14; i. un anticuerpo cuya HC comprende la secuencia de aminoácidos de la SEQ ID Nº 11; 25 j. un anticuerpo cuya LC comprende la secuencia de aminoácidos de la SEQ ID Nº 12; k. un anticuerpo cuya HC comprende la secuencia de aminoácidos de la SEQ ID Nº 13; y l. un anticuerpo cuya LC comprende la secuencia de aminoácidos de la SEQ ID Nº 14. Reivindicación 10: Una molécula de ácido nucleico aislada que comprende una secuencia de nucleótidos que codifica la cadena pesada o una porción de unión a antígeno de la misma, una secuencia de nucleótidos que codifica la cadena ligera o una porción de unión a antígeno de la misma, o ambas, del anticuerpo anti-MET de una cualquiera de las reivindicaciones 1 - 9. Reivindicación 12: Un vector que comprende la molécula de ácido nucleico aislada de la reivindicación 10 u 11, en donde dicho vector comprende además una secuencia de control de la expresión. Reivindicación 13: Una célula huésped que comprende una secuencia de nucleótidos que codifica la cadena pesada o una porción de unión a antígeno de la misma y/o una secuencia de nucleótidos que codifica la cadena ligera o una porción de unión a antígeno de la misma del anticuerpo anti-MET de una cualquiera de las reivindicaciones 1 - 9. Reivindicación 17: Una molécula de unión biespecífica que tiene las especificidades de unión del anticuerpo anti-MET o porción de unión a antígeno del mismo de la reivindicación 1. Reivindicación 19: Un conjugado de anticuerpo fármaco (ADC) de fórmula Ab-(L-D)ₚ, en donde Ab es el anticuerpo anti-MET o una porción de unión a antígeno del mismo de la reivindicación 1, D es una carga útil o resto de fármaco, L es un conector que une covalentemente Ab a D, y p es un número entero de 1 a 16. Reivindicación 22: Una composición que comprende el anticuerpo anti-MET o porción de unión a antígeno de una cualquiera de las reivindicaciones 1 - 9, la molécula de unión biespecífica de una cualquiera de las reivindicaciones 17 - 18 o el ADC de una cualquiera de las reivindicaciones 19 - 21. Reivindicación 23: Una composición farmacéutica que comprende la composición de la reivindicación 22 y un excipiente farmacéuticamente aceptable. Reivindicación 24: Un método para producir el anticuerpo o porción de unión a antígeno del mismo de una cualquiera de las reivindicaciones 1 - 9, que comprende proporcionar una célula huésped según una cualquiera de las reivindicaciones 13 - 14, cultivar dicha célula huésped en condiciones adecuadas para la expresión del anticuerpo o porción, y aislar el anticuerpo o porción resultante.The present invention relates to a novel recombinant antibody or antigen-binding portion thereof directed to MET, as well as to ADCs comprising this antibody or antigen-binding portion thereof, compositions comprising this antibody or antigen-binding portion thereof, compositions comprising ADCs comprising said anti-MET antibody or antigen-binding portion thereof, to the use of said antibody or antigen-binding portion thereof or of said ADCs or of said compositions comprising anti-MET antibody or anti-MET ADC. Claim 1: An anti-MET antibody or an antigen-binding portion thereof, wherein said antibody is selected from the group consisting of: a. an antibody whose H-CDR1, H-CDR2, H-CDR3 comprise the amino acid sequences of SEQ ID NO: 1, 2, and 3, respectively; b. an antibody whose L-CDR1, L-CDR2, L-CDR3 comprise the amino acid sequences of SEQ ID NOs: 4, 5, and 6, respectively; c. an antibody whose VH is at least 90% identical in sequence to the amino acid sequence of SEQ ID NO: 7; d. an antibody whose VL is at least 90% identical in sequence to the amino acid sequence of SEQ ID NO: 8; e. an antibody whose VH comprises the amino acid sequence of SEQ ID NO: 7; f. an antibody whose VL comprises the amino acid sequence of SEQ ID NO: 8; g. an antibody whose HC is at least 90% identical in sequence to the amino acid sequence of SEQ ID NO: 11 or 13; h. an antibody whose LC is at least 90% identical in sequence to the amino acid sequence of SEQ ID NO: 12 or 14; i. an antibody whose HC comprises the amino acid sequence of SEQ ID NO: 11; j. an antibody whose LC comprises the amino acid sequence of SEQ ID NO: 12; k. an antibody whose HC comprises the amino acid sequence of SEQ ID NO: 13; and l. an antibody whose LC comprises the amino acid sequence of SEQ ID NO: 14. Claim 10: An isolated nucleic acid molecule comprising a nucleotide sequence encoding the heavy chain or an antigen-binding portion thereof, a nucleotide sequence encoding the light chain or an antigen-binding portion thereof, or both, of the anti-MET antibody of any one of claims 1 - 9. Claim 12: A vector comprising the isolated nucleic acid molecule of claim 10 or 11, wherein said vector further comprises an expression control sequence. Claim 13: A host cell comprising a nucleotide sequence encoding the heavy chain or an antigen-binding portion thereof and/or a nucleotide sequence encoding the light chain or an antigen-binding portion thereof of the anti-MET antibody of any one of claims 1 - 9. Claim 17: A bispecific binding molecule having the binding specificities of the anti-MET antibody or antigen-binding portion thereof of claim 1. Claim 19: An antibody drug conjugate (ADC) of formula Ab-(L-D)ₚ, wherein Ab is the anti-MET antibody or antigen-binding portion thereof of claim 1, D is a payload or drug moiety, L is a linker that covalently links Ab to D, and p is an integer from 1 to 16. Claim 22: A composition comprising the anti-MET antibody or antigen-binding portion of any one of claims 1 - 9, the bispecific binding molecule of any one of claims 17 - 18 or the ADC of any one of claims 19 - 21. Claim 23: A pharmaceutical composition comprising the composition of claim 22 and a pharmaceutically acceptable excipient. Claim 24: A method of producing the antibody or antigen-binding portion thereof of any one of claims 1 - 9, comprising providing a host cell according to any one of claims 13 - 14, culturing said host cell under conditions suitable for expression of the antibody or portion, and isolating the resulting antibody or portion.

ARP240101252A 2023-05-19 2024-05-17 ANTI-MET ANTIBODIES, ADCs, THEIR COMPOSITIONS AND USES AR132710A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP23315207 2023-05-19

Publications (1)

Publication Number Publication Date
AR132710A1 true AR132710A1 (en) 2025-07-23

Family

ID=87001902

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP240101252A AR132710A1 (en) 2023-05-19 2024-05-17 ANTI-MET ANTIBODIES, ADCs, THEIR COMPOSITIONS AND USES

Country Status (4)

Country Link
AR (1) AR132710A1 (en)
AU (1) AU2024277829A1 (en)
TW (1) TW202500584A (en)
WO (1) WO2024240634A1 (en)

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4510245A (en) 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
US4740461A (en) 1983-12-27 1988-04-26 Genetics Institute, Inc. Vectors and methods for transformation of eucaryotic cells
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
DE3668186D1 (en) 1985-04-01 1990-02-15 Celltech Ltd TRANSFORMED MYELOMA CELL LINE AND METHOD USING THE SAME FOR EXPRESSING A GENE ENCODING AN EUKARYONTIC POLYPEPTIDE.
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4959455A (en) 1986-07-14 1990-09-25 Genetics Institute, Inc. Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
US4912040A (en) 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
US5750172A (en) 1987-06-23 1998-05-12 Pharming B.V. Transgenic non human mammal milk
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US5633076A (en) 1989-12-01 1997-05-27 Pharming Bv Method of producing a transgenic bovine or transgenic bovine embryo
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
ES2139598T3 (en) 1990-07-10 2000-02-16 Medical Res Council PROCEDURES FOR THE PRODUCTION OF SPECIFIC UNION COUPLE MEMBERS.
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
WO1992009690A2 (en) 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with altered binding properties
ATE439435T1 (en) 1991-03-01 2009-08-15 Dyax Corp CHIMERIC PROTEIN COMPRISING MICROPROTEIN HAVING TWO OR MORE DISULFIDE BONDS AND FORMATIONS THEREOF
EP1471142B1 (en) 1991-04-10 2008-11-19 The Scripps Research Institute Heterodimeric receptor libraries using phagemids
DE4122599C2 (en) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid for screening antibodies
EP0605522B1 (en) 1991-09-23 1999-06-23 Medical Research Council Methods for the production of humanized antibodies
ATE193301T1 (en) 1993-03-09 2000-06-15 Genzyme Corp METHOD FOR ISOLATION OF PROTEINS FROM MILK
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US6046037A (en) 1994-12-30 2000-04-04 Hiatt; Andrew C. Method for producing immunoglobulins containing protection proteins in plants and their use
GB2339430A (en) 1997-05-21 2000-01-26 Biovation Ltd Method for the production of non-immunogenic proteins
AU770555B2 (en) 1998-08-17 2004-02-26 Abgenix, Inc. Generation of modified molecules with increased serum half-lives
DE69934967T2 (en) 1998-12-08 2007-12-06 Biovation Ltd. METHOD FOR REDUCING IMMUNOGENICITY OF PROTEINS
US6517529B1 (en) 1999-11-24 2003-02-11 Radius International Limited Partnership Hemodialysis catheter
DK1583830T3 (en) 2003-01-07 2007-01-15 Symphogen As Process for Preparation of Recombinant Polyclonal Proteins
TWI333977B (en) 2003-09-18 2010-12-01 Symphogen As Method for linking sequences of interest
US7476724B2 (en) 2004-08-05 2009-01-13 Genentech, Inc. Humanized anti-cmet antibodies
PT2152872E (en) 2007-05-25 2010-11-17 Symphogen As Method for manufacturing a recombinant polyclonal protein
MX2010011293A (en) 2008-04-23 2010-12-20 Symphogen As Methods for manufacturing a polyclonal protein.
PA8849001A1 (en) 2008-11-21 2010-06-28 Lilly Co Eli C-MET ANTIBODIES
US9217039B2 (en) 2010-11-01 2015-12-22 Symphogen A/S Anti-HER3 antibodies and compositions
WO2012059561A1 (en) 2010-11-03 2012-05-10 Argen-X-Bv Anti c-met antibodies
US20140154251A1 (en) 2011-10-05 2014-06-05 Samsung Electronics Co., Ltd. Anti c-met antibody and uses thereof
US20140069822A1 (en) 2012-09-10 2014-03-13 Antec Leyden B.V. Electrochemical reduction of disulfide bonds in proteinaceous substances and electrochemical cell for carrying out such reduction
DK2922872T3 (en) 2012-11-21 2019-01-02 Janssen Biotech Inc BISPECIFIC EGFR / C-MET ANTIBODIES
CN107001471B (en) 2014-09-16 2022-01-18 西福根有限公司 anti-MET antibodies and compositions
PT3458102T (en) 2016-05-17 2020-08-17 Abbvie Inc Anti-cmet antibody drug conjugates and methods for their use

Also Published As

Publication number Publication date
AU2024277829A1 (en) 2025-12-04
TW202500584A (en) 2025-01-01
WO2024240634A1 (en) 2024-11-28

Similar Documents

Publication Publication Date Title
KR101789343B1 (en) Rsv-specific binding molecule
DK1597280T4 (en) Preparation of monoclonal antibodies by EBV transformation of B cells
PE20181952A1 (en) ANTI-LL-33 ANTIBODIES, COMPOSITIONS, METHODS AND USES OF THE SAME
AR115769A1 (en) MESOTHELINE AND CD137 BINDING MOLECULES
AR110755A1 (en) BONE DIRECTED ANTIBODIES
BRPI1011195B1 (en) methods to produce a collection of nucleic acids
HRP20150887T1 (en) Novel antibodies inhibiting c-met dimerization, and uses thereof
JP2017534259A5 (en)
RU2009123409A (en) NEW ANTIPROLIFERATIVE ANTIBODIES
RU2012145232A (en) HUMANIZED ANTIBODIES TO CXCR4 FOR CANCER TREATMENT
BRPI0717882A2 (en) METHODS FOR INCREASING PRODUCTION OF A HUMANIZED ANTIBODY, HUMANIZED MURIN OR PARENTAL ANTIBODY; OR A FRAGMENT, EPITOPO CONNECTION FRAGMENT OR ANTIGEN CONNECTION FRAGMENT OF THE SAME IN A CELL HOSTED BY THE SEQUENCE, ANTIBODY AND ANTIBODY ANTIBODY AND FRAGMENT OF ANOPYCUS AND ANTIBODY CONNECTION
WO2009054873A9 (en) Anti-rantes antibodies and methods of use thereof
AR124895A1 (en) ANTI-CD30L ANTIBODIES AND THEIR USES
AR124084A1 (en) HEAVY CHAIN ANTIBODIES THAT BIND THE α-FOLATE RECEPTOR
RU2020113713A (en) Fusion Protein Containing FGF-18 Molecule
AR129935A1 (en) ANTIBODY, LINKS, ACTIVE CARGO, CONJUGATES AND THEIR APPLICATIONS
AR123728A1 (en) CD1A ANTIBODIES AND THEIR USE
AR132710A1 (en) ANTI-MET ANTIBODIES, ADCs, THEIR COMPOSITIONS AND USES
EP2398823B1 (en) Monoclonal antibodies against vaginolysin
US20240254204A1 (en) Protein antigen-binding molecules
CL2023001294A1 (en) Antigen-binding domain with reduced clipping rate
AR132668A1 (en) ANTIBODIES CAPABLE OF BINDING TO OX40, VARIANTS THEREOF AND THEIR USES
AR125040A1 (en) ANTI-VISION CONSTRUCTS AND THEIR USES
AR132805A1 (en) Immunostimulatory antigen-binding molecules that specifically bind to BCMA
AR129489A1 (en) ANTI-BMP9 ANTIBODIES AND METHODS OF USE THEREOF